Carnegie Investment Counsel Buys 61,560 Shares of Hims & Hers Health, Inc. $HIMS

Carnegie Investment Counsel increased its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 25.4% in the third quarter, HoldingsChannel reports. The firm owned 303,909 shares of the company’s stock after buying an additional 61,560 shares during the period. Carnegie Investment Counsel’s holdings in Hims & Hers Health were worth $17,238,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in HIMS. Invesco Ltd. lifted its position in shares of Hims & Hers Health by 502.2% during the second quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock valued at $127,237,000 after buying an additional 2,128,587 shares during the last quarter. Clear Street LLC purchased a new stake in Hims & Hers Health during the second quarter valued at approximately $83,582,000. Norges Bank acquired a new stake in Hims & Hers Health in the second quarter valued at approximately $78,464,000. Marex Group plc acquired a new stake in Hims & Hers Health in the second quarter valued at approximately $53,626,000. Finally, Man Group plc grew its holdings in Hims & Hers Health by 345.9% in the second quarter. Man Group plc now owns 816,582 shares of the company’s stock worth $40,707,000 after purchasing an additional 633,432 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Buying and Selling

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 85,000 shares of the company’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $60.20, for a total value of $5,117,000.00. Following the completion of the transaction, the chief financial officer owned 70,232 shares in the company, valued at approximately $4,227,966.40. This represents a 54.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Michael Chi sold 13,750 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $504,762.50. Following the sale, the chief operating officer owned 305,161 shares in the company, valued at $11,202,460.31. This trade represents a 4.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 230,835 shares of company stock valued at $11,113,714 in the last ninety days. Company insiders own 13.71% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the company. KeyCorp started coverage on Hims & Hers Health in a report on Tuesday, October 21st. They set a “sector weight” rating for the company. BTIG Research reiterated a “buy” rating and issued a $85.00 price target on shares of Hims & Hers Health in a research note on Tuesday, November 4th. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday. Barclays started coverage on shares of Hims & Hers Health in a report on Monday, December 8th. They set an “overweight” rating and a $48.00 price objective on the stock. Finally, Leerink Partnrs upgraded shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, December 4th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $45.50.

Hims & Hers Health Stock Down 1.0%

Shares of HIMS stock opened at $34.33 on Friday. Hims & Hers Health, Inc. has a twelve month low of $23.97 and a twelve month high of $72.98. The stock has a market cap of $7.81 billion, a P/E ratio of 63.57, a P/E/G ratio of 6.86 and a beta of 2.41. The stock has a 50 day moving average of $39.70 and a 200 day moving average of $47.83. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The firm had revenue of $598.98 million for the quarter, compared to analyst estimates of $578.99 million. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.Hims & Hers Health’s revenue for the quarter was up 49.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.32 EPS. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health declared that its Board of Directors has initiated a share repurchase plan on Monday, November 17th that allows the company to buyback $250.00 million in outstanding shares. This buyback authorization allows the company to buy up to 3% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.